Related Experiment Video

Updated: May 19, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Growth failure in children with cystic fibrosis

Alessandra Scaparrotta1, Sabrina Di Pillo, Marina Attanasi

  • 1Department of Pediatrics, University of Chieti, Italy. ale.scaparrotta@libero.it

Journal of Pediatric Endocrinology & Metabolism : JPEM
|August 11, 2012
PubMed

Insights

Poor linear growth in children with cystic fibrosis (CF) is linked to malnutrition, inflammation, and lung disease. Early diagnosis and nutritional support are crucial for improving growth and overall prognosis in CF patients.

Area of Science:

  • Pediatrics
  • Genetics
  • Pulmonology

Background:

  • Poor linear growth and inadequate weight gain are prevalent issues in pediatric cystic fibrosis (CF).
  • Key contributing factors include malnutrition, chronic inflammation, lung disease, and corticosteroid use.
  • Despite catch-up growth post-diagnosis, deficits in height and weight persist into adulthood.

Purpose of the Study:

  • To elucidate the etiological and pathogenetic mechanisms underlying growth failure in children with CF.
  • To clarify the impact of these mechanisms on disease morbidity and clinical outcomes.
  • To emphasize the relationship between growth failure and progressive pulmonary function decline.

Main Methods:

  • Literature review of studies on cystic fibrosis growth failure.
  • Analysis of etiological factors: nutrition, inflammation, lung disease, and medical treatments.
  • Examination of the impact on morbidity, clinical outcomes, and pulmonary function.

Main Results:

  • Identified undernutrition, chronic inflammation, lung disease, and corticosteroid treatment as primary drivers of growth failure.
  • Highlighted the importance of nutritional support and recombinant human growth hormone therapy.
  • Emphasized that early diagnosis is critical for better nutritional status, growth, and potentially improved respiratory outcomes.

Conclusions:

  • Growth failure in CF is multifactorial, significantly impacting morbidity and clinical outcomes.
  • Early diagnosis and intervention, including nutritional support, are essential for optimizing growth and prognosis in CF children.
  • Addressing growth failure is integral to managing CF and mitigating progressive pulmonary decline.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...